Results 61 to 70 of about 53,113 (297)

2190P First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC) [PDF]

, 2023
George Evangelou, Ioannis Vamvakaris, V. Kolintzikis, Vasiliki Nikolaidou, Oraianthi Fiste, Vasiliki Koliaraki, Ηλίας Κοττέας, Konstantinos Syrigos   +7 more
openalex   +1 more source

Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer

Advanced Science, EarlyView.
Corticosteroids improve the efficacy of immune checkpoint blockade therapy in metastatic murine breast cancer. By normalizing the tumor immune microenvironment, corticosteroids reduce immunosuppressive signals, restore T‐cell function, and promote antitumor immune responses, resulting in enhanced tumor control.
John D. Martin, Koji Nagaoka, Myrofora Panagi, Akihiro Hosoi, Fotios Mpkeris, Pengwen Chen, Thahomina T. Khan, Margaret R. Martin, Changbo Sun, Chrysovalantis Voutouri, Maria Louca, Panagiotis Papageorgis, Akira Sumiyoshi, Nobuhiro Nitta, Kazuyoshi Takeda, Ichio Aoki, Kazunori Kataoka, Triantafyllos Stylianopoulos, Kazuhiro Kakimi, Horacio Cabral   +19 more
wiley   +1 more source

6ER-033 Pembrolizumab and atezolizumab as possible equivalent first-line therapeutic alternatives in PD-L1-expressing triple-negative breast cancer [PDF]

, 2023
MD Rivas Rodríguez, Á Gil García, A Rojas Albarrán, M Gragera Gomez, H Vázquez Velázquez   +4 more
openalex   +1 more source

Mutual Exclusion Analysis Shows that DUSP9 Negatively Regulates PD‐L1 Expression and Acts as a Target to Enhance Anti‐PD‐1 Efficacy

Advanced Science, EarlyView.
A mutually exclusive screening system is established to identify negative regulators of highly plastic genes. Dual specificity phosphatase (DUSP9) is a novel negative regulatory molecule of PD‐L1 by dephosphorylating STAT3, and acts as a target molecule in combination with PD‐1 antibody for tumor immunotherapy and a new clinical biomarker for ...
Yuzhe Hu, Ling Tang, Zheng Kuang, Danyi Huang, Ting Li, Gaofei Yin, Yingyu Chen, Wei Guo, Wenling Han, Pingzhang Wang   +9 more
wiley   +1 more source

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

Frontiers in Oncology
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +8 more
doaj   +1 more source

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Liver Cancer, 2021
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150.
Shukui Qin, Zhenggang Ren, Yin-Hsun Feng, Thomas Yau, Baocheng Wang, Haitao Zhao, Yuxian Bai, Shanzhi Gu, Lindong Li, Sairy Hernandez, Derek-Zhen Xu, Sohail Mulla, Yifan Wang, Hui Shao, Ann Lii Cheng   +14 more
doaj   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Advanced atypical lung carcinoid tumour successfully treated with carboplatin, etoposide and atezolizumab: A case report [PDF]

, 2022
Yoshihiro Yamamoto, Kayo Ijichi, Ai Koike, Satoshi Nakamura, Yuriko Takahata, Yuki Okamatsu, Akitaka Fujita, Satoru Kawakami, Taishi Harada   +8 more
openalex   +1 more source

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

Advanced Science, EarlyView.
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley   +1 more source

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

Journal for ImmunoTherapy of Cancer
Background Options remain limited for patients requiring later lines of therapy for metastatic non-small cell lung cancer (mNSCLC) due to poor prognosis and potential toxicities.
Enriqueta Felip, Francois Ghiringhelli, Alona Zer, Byoung Chul Cho, Sun Min Lim, Laurent Greillier, Alastair Greystoke, Nuria Pardo, Yaacov R Lawrence, Nedal Al-Sakaff, Hans-Joachim Helms, Hen Prizant, Jan Pintoffl, Farah Louise Lim   +13 more
doaj   +1 more source